Panbela Announces Poster Presentation At The Endocrine Society Meeting: Polyamine Inhibition And β-Cell Preservation In Recent Onset Type 1 Diabetes
Portfolio Pulse from Happy Mohamed
Panbela Therapeutics announces a poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting. The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF. Panbela is providing the drug at no cost to researchers.
June 26, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Panbela Therapeutics presents positive results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting, potentially leading to increased interest in the company's stock.
The positive results for CPP-1X in recent onset type 1 diabetes presented at the Endocrine Society meeting may lead to increased interest in Panbela Therapeutics' stock. The company's collaboration with Indiana University School of Medicine and support from JDRF further strengthens its position in the market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100